Other Team Members

This updated Treatment Improvement Protocol (TIP) is designed to help providers and others better understand how to identify, manage, and prevent substance misuse in older adults.

This guide helps health care providers, systems, and communities support recovery from substance use disorders via employment mechanisms. 

This TIP supports learning about the key aspects, functions, and uses of Peer Support Services (PSS) in recovery from problematic substance use, which will help providers, supervisors, and administrators in SUD treatment programs better understand and respond to these changes.

The RODS is an 8-item screening tool to assess opioid depdence and the need for services for opioid use or withdrawal that require medical attention.

This fact sheet includes basic descriptions of medications for opioid use disorders (MOUD) including naltrexone, buprenorphine, and methadone. It also addresses how MOUD can help those struggling with opioid use disorder, misunderstandings about MOUD, and additional considerations.

This web page provides frequently asked questions for rules on prescribing buprenorphine and other and other medications for opioid use disorder (MOUD), following 2023 policy updates.

This web page provides frequently asked questions regarding the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This letter announces details on the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).